Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | MASP2 | O00187 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 4/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | NAMPT | P43490 | 4/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30765788 | 0.87 | NTRK1 (0.38) | NTRK1KMT2APOLBTP53 | |
| SCHEMBL30765947 | 0.78 | LMNA (0.40) | KMT2AMAPTPOLBTP53 | |
| SCHEMBL30765705 | 0.73 | ALDH1A1 (0.38) | KMT2AMAPTTP53 | |
| SCHEMBL30765769 | 0.72 | NTRK1 (0.40) | NTRK1MASP2F2POLBNTRK3 | |
| SCHEMBL30765718 | 0.72 | NTRK1 (0.45) | NTRK1MASP2KMT2AMTNR1BF2 | |
| SCHEMBL30765891 | 0.71 | GAA (0.40) | KMT2AMAPTPOLBTP53 | |
| SCHEMBL30765865 | 0.71 | NTRK1 (0.37) | NTRK1MASP2KMT2AF2NAMPT | |
| SCHEMBL30765582 | 0.71 | KDM4C (0.42) | NTRK1MAPTMTNR1BPOLBCYP2C9 | |
| SCHEMBL30765506 | 0.70 | NTRK1 (0.51) | NTRK1NTRK3 | |
| SCHEMBL31558522 | 0.68 | MTNR1B (0.45) | NTRK1MAPTMTNR1BNAMPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4568666-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | Alexion Pharmaceuticals, Inc. (US) | 2025-06-18 | — | — | EP | disclosed |
| CN-119768164-A | Pharmaceutical compounds for treating complement-mediated disorders | 阿雷克森制药公司 | 2025-04-04 | — | — | CN | disclosed |
| WO-2024035686-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-15 | — | — | WO | disclosed |